MX2013002511A - Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado. - Google Patents

Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado.

Info

Publication number
MX2013002511A
MX2013002511A MX2013002511A MX2013002511A MX2013002511A MX 2013002511 A MX2013002511 A MX 2013002511A MX 2013002511 A MX2013002511 A MX 2013002511A MX 2013002511 A MX2013002511 A MX 2013002511A MX 2013002511 A MX2013002511 A MX 2013002511A
Authority
MX
Mexico
Prior art keywords
fusionated
profilaxis
triazols
treatment
moderate cognitive
Prior art date
Application number
MX2013002511A
Other languages
English (en)
Spanish (es)
Inventor
Tatsuki Koike
Takafumi Takai
Yasutaka Hoashi
Tetsuya Tsukamoto
Makoto Kamata
Minoru Nakamura
Yoshihide Tomata
Yuichi Kajita
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013002511(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MX2013002511A publication Critical patent/MX2013002511A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2013002511A 2010-09-02 2011-09-01 Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado. MX2013002511A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010197064 2010-09-02
JP2011143548 2011-06-28
PCT/JP2011/070419 WO2012029991A1 (en) 2010-09-02 2011-09-01 Fused triazoles for the treatment or prophylaxis of mild cognitive impairment

Publications (1)

Publication Number Publication Date
MX2013002511A true MX2013002511A (es) 2013-07-29

Family

ID=45094181

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002511A MX2013002511A (es) 2010-09-02 2011-09-01 Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado.

Country Status (22)

Country Link
US (3) US8901309B2 (OSRAM)
EP (1) EP2611805A1 (OSRAM)
JP (1) JP5871909B2 (OSRAM)
KR (1) KR20130139895A (OSRAM)
CN (1) CN103249733A (OSRAM)
AR (1) AR082865A1 (OSRAM)
AU (1) AU2011296887A1 (OSRAM)
BR (1) BR112013004746A2 (OSRAM)
CA (1) CA2809779A1 (OSRAM)
CL (1) CL2013000575A1 (OSRAM)
DO (1) DOP2013000051A (OSRAM)
EA (1) EA201390333A1 (OSRAM)
EC (1) ECSP13012535A (OSRAM)
MA (1) MA34556B1 (OSRAM)
MX (1) MX2013002511A (OSRAM)
PE (1) PE20131305A1 (OSRAM)
PH (1) PH12013500403A1 (OSRAM)
SG (1) SG187917A1 (OSRAM)
TW (1) TW201213327A (OSRAM)
UY (1) UY33586A (OSRAM)
WO (1) WO2012029991A1 (OSRAM)
ZA (1) ZA201301929B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2011007756A1 (ja) * 2009-07-13 2012-12-27 武田薬品工業株式会社 複素環化合物及びその用途
MX2013002511A (es) * 2010-09-02 2013-07-29 Takeda Pharmaceutical Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado.
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
RU2563254C2 (ru) * 2013-07-08 2015-09-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения производных 7-(гетеро)арил-4,5,6,7-тетрагидро[1,2,3]триазоло[1,5-a]пиридина
JP7000160B2 (ja) * 2015-05-12 2022-01-19 エフ エム シー コーポレーション 除草剤としてのアリール置換二環式化合物
US11603440B2 (en) * 2019-09-12 2023-03-14 Dupont Electronics, Inc. Polyimide films and electronic devices
EP4448100A4 (en) * 2021-12-17 2025-10-22 Athira Pharma Inc USES OF BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1261610A2 (en) 2000-02-17 2002-12-04 Bristol-Myers Squibb Pharma Company Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production
MXPA05012281A (es) 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
EP1678172B1 (en) * 2003-10-15 2009-12-09 Targacept, Inc. Azabicyclic compounds for relieving pain and treating central nervous system disorders
BRPI0511504A (pt) 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
EP1808432B1 (en) 2004-10-26 2010-02-24 Eisai R&D Management Co., Ltd. Amorphous form of cinnamide compound
AU2007205066A1 (en) 2006-01-11 2007-07-19 Merck & Co., Inc. Fused triazole tachykinin receptor antagonists
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
CA2643796A1 (en) 2006-03-09 2007-09-13 Eisai R & D Management Co., Ltd. Polycyclic cinnamide derivatives
TW200808800A (en) 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
EP2119719A1 (en) 2006-12-26 2009-11-18 Daiichi Sankyo Company, Limited Thiazepine derivative
WO2008077649A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infectons
AU2008214372A1 (en) 2007-02-08 2008-08-14 Merck Sharp & Dohme Corp. Therapeutic agents
MX2010006243A (es) 2007-12-06 2010-08-31 Schering Corp Moduladores de gamma secretasa.
TW201030002A (en) * 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2010197064A (ja) 2009-02-23 2010-09-09 Chugoku Electric Power Co Inc:The 直下位置測定装置
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
EP2615090A1 (en) * 2009-02-26 2013-07-17 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
JP2012051806A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
WO2011002067A1 (ja) 2009-07-02 2011-01-06 武田薬品工業株式会社 複素環化合物およびその用途
JPWO2011007756A1 (ja) 2009-07-13 2012-12-27 武田薬品工業株式会社 複素環化合物及びその用途
US8946266B2 (en) 2009-07-15 2015-02-03 Janssen Pharmaceuticals, Inc. Substituted triazole and imidazole derivatives as gamma secretase modulators
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
WO2011016559A1 (ja) 2009-08-07 2011-02-10 武田薬品工業株式会社 複素環化合物およびその用途
JP2011143548A (ja) 2010-01-12 2011-07-28 Panasonic Corp スクリーン印刷機及びスクリーン印刷方法
EP2523949B1 (en) 2010-01-15 2014-08-20 Janssen Pharmaceuticals Inc. Novel substituted triazole derivatives as gamma secretase modulators
MX2013002511A (es) * 2010-09-02 2013-07-29 Takeda Pharmaceutical Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado.

Also Published As

Publication number Publication date
WO2012029991A1 (en) 2012-03-08
TW201213327A (en) 2012-04-01
EP2611805A1 (en) 2013-07-10
PH12013500403A1 (en) 2013-03-25
US8822699B2 (en) 2014-09-02
DOP2013000051A (es) 2013-04-30
KR20130139895A (ko) 2013-12-23
US20120059030A1 (en) 2012-03-08
UY33586A (es) 2012-03-30
AR082865A1 (es) 2013-01-16
US8901309B2 (en) 2014-12-02
MA34556B1 (fr) 2013-09-02
EA201390333A1 (ru) 2013-08-30
JP2013536798A (ja) 2013-09-26
AU2011296887A1 (en) 2013-04-11
ZA201301929B (en) 2013-11-27
SG187917A1 (en) 2013-04-30
CA2809779A1 (en) 2012-03-08
CN103249733A (zh) 2013-08-14
US20140350260A1 (en) 2014-11-27
BR112013004746A2 (pt) 2016-06-07
ECSP13012535A (es) 2013-06-28
JP5871909B2 (ja) 2016-03-01
PE20131305A1 (es) 2013-10-31
US20130178497A1 (en) 2013-07-11
CL2013000575A1 (es) 2013-08-23

Similar Documents

Publication Publication Date Title
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
MX2013006113A (es) Compuestos biciclico.
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
UY35821A (es) Compuesto heterocíclico
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
CR20150217A (es) Inhibidores de histona demetilasas
MX373307B (es) Compuestos de biaril-amida como inhibidores de cinasa.
CR20120448A (es) Compuesto heterocíclico
CR20120064A (es) Heterociclos microbicidas
DOP2015000140A (es) Compuesto heterocíclico
MX2013002511A (es) Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado.
ECSP11011244A (es) Nuevos herbicidas.
MX2014014832A (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa.
ECSP11011245A (es) Novedosos herbicidas
ECSP17010238A (es) Compuestos novedosos de pirimidina sustituidos
ECSP14011792A (es) Inhibidores de iap
UY36263A (es) Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso
MX2016003892A (es) Uso de dihidrooxindolilsulfonamidas sustituidas, o sus sales, para aumentar la tolerancia de plantas al estres.
BR112012017393A2 (pt) derivados de 2,5,7-oxazolpirimidina substituída
CR20140495A (es) 5-amino[1,4]thiazines como inhibidores de bace1
MX2017002312A (es) Compuestos heterobiciclicos y su uso para el tratamiento de tuberculosis.
CL2016001623A1 (es) Compuestos de benzamida y nicotinamida y métodos para usar los mismos.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal